Search

Displaying results 2461 - 2470 of 10000 in total
  1. Drug

    Lucinactant

    go.drugbank.com/drugs/DB04897
    Approved

    FDA approved on March 6, 2012.

  2. Drug

    Leniolisib

    go.drugbank.com/drugs/DB16217
    ApprovedInvestigational

    The FDA approved leniolisib on March 24, 2023, making it the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS).

  3. Drug

    Benfluorex

    go.drugbank.com/drugs/DB09022
    ApprovedWithdrawn

    The European Medicines Agency (EMA) recommended withdrawing all benfluorex containing medicines on 18 December 2009.

  4. Drug

    MF-300

    go.drugbank.com/drugs/DB32060
    Investigational

    MF-300 is an investigational, first-in-class, small molecule inhibitor of 15-hydroxyprostaglandin dehydrogenase.

  5. Drug

    Tosedostat

    go.drugbank.com/drugs/DB11781
    Investigational

    Tosedostat is an inhibitor of the M1 family of aminopeptidases, in particular PuSA, and LTA4 hydrolase.

  6. Drug

    Ublituximab

    go.drugbank.com/drugs/DB11850
    ApprovedInvestigational

    [A244210, A244215,A241045] Ublituximab was initially developed by LFB Group but was licensed to TG Therapeutics in 2012. … [A244210] Ublituximab is a chimeric anti-CD20 IgG1κ antibody produced in the rat YB2/0 cell line to target a unique epitope and enhance ADCC compared to other approved anti-CD20 antibodies such as [rituximab

  7. Drug

    Bazedoxifene

    go.drugbank.com/drugs/DB06401
    ApprovedInvestigational

    Bazedoxifene is a third generation selective estrogen receptor modulator (SERM), developed by Pfizer following the completion of their takeover of Wyeth Pharmaceuticals. In late 2013, Pfizer received approval for bazedoxifene as part of ...

    Mixtures: DUAVIVE 20 mg/0.45 mg modified - release tablets, DUAVİVE 0.45 MG/20 MG DEĞİŞTİRİLMİŞ SALIMLI TABLET, 30 TABLET
  8. Drug

    Florquinitau (18F)

    go.drugbank.com/drugs/DB19215
    Approved

    [L64052,L64053] It is the second fluorine-18 tau PET imaging agent approved in the United States, after flortaucipir (Tauvid), which was approved in 2020.[L64054,L14114] … [L64052] Florquinitau F 18, also known as MK-6240, was approved by the FDA on August 14, 2026 for PET of the brain in adults with cognitive impairment who are being evaluated for Alzheimer's disease

  9. Drug

    Synthetic Conjugated Estrogens, A

    go.drugbank.com/drugs/DB09317
    Approved

    Prior to menopause, the primary source of estrogen is the ovarian follicle, which secretes 70-500 micrograms of estradiol daily, depending on the phase of the menstrual cycle. … There is currently no generic form of CEEs available as a detailed analytical characterization of the active ingredients or of their estrogenic activity is not available at this time.

  10. Drug

    UCB7362

    go.drugbank.com/drugs/DB17096
    Experimental

    It has shown high potency in biochemical (IC<sub>50</sub> = 7 nM), _in vitro_ (_P. falciparum_ 3D7 lactate dehydrogenase growth inhibition assay IC<sub>50</sub> = 10 nM), and _in vivo_ (50 mg/kg dose